Merck’s big ADC move; Latest from #ESMO23; How Eli Lilly is thinking about deals; AI-designed drugs face reckoning in clinic; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

As Rey­nald Cas­tañe­da, Kyle LaHu­cik and Lei Lei Wu bring us the lat­est ES­MO news out of Madrid, don’t for­get to sign up for our vir­tu­al event on Mon­day to get the ex­perts’ take on where can­cer re­search is now and where we are head­ed next.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.